<DOC>
	<DOCNO>NCT00572000</DOCNO>
	<brief_summary>The purpose study assess occurrence serious adverse event ( SAEs ) well evaluate occurrence solicit local solicit general symptom occurrence medically significant condition report throughout study period .</brief_summary>
	<brief_title>Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Human Papillomavirus ( HPV ) Vaccine Healthy Vietnamese Women According 0 , 1 , 6 Month Schedule</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol ( e.g. , completion diary card , return vaccination visit followup visit ) enrol study . The female subject : married Vietnamese origin , reside Vietnam , , include , 25 40 year age time first vaccination . Written inform consent obtain subject ( prior enrolment ) . Healthy subject establish medical history clinical examination enter study . Subjects must negative urine pregnancy test . Subjects childbearing potential ( i.e . active menstrual cycle ) time study entry : must pregnant must abstinent ( , must document source document vaccination visit ) must use adequate contraceptive precaution ( i.e . intrauterine contraceptive device , oral contraceptive , diaphragm condom combination contraceptive jelly , cream foam , progestogenonly implantable cutaneous hormonal patch injectable contraceptive ) 30 day prior vaccination must agree continue precaution one month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period one month last vaccine dose . Subjects deliver recently breastfeed woman must complete period least 3 month postpregnancy breastfeed order enrol study . Planning become pregnant likely become pregnant ( determined investigator ) planning discontinue contraceptive precaution study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug 14 consecutive day within six month prior first vaccine dose one month last dose vaccine . ( For corticosteroid , mean prednisone , equivalent , ≥ 0.5 mg/kg/day . Inhaled topical steroid allow ) . Planned administration/administration vaccine foreseen study protocol within 30 day ( Days 1 30 ) 30 day ( i.e . Days 0 29 ) first dose vaccine . However , administration tetanus toxoid vaccine 8 day first dose study vaccine allow . Enrolment defer subject outside specify window . Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period . Any medically diagnose suspect immunodeficient condition human immunodeficiency virus ( HIV ) infection base medical history physical examination ( laboratory testing require ) . History allergic disease , suspect allergy reaction likely exacerbate component study vaccine , e.g . AS04 , aluminium , MPL . Hypersensitivity latex ( find syringetip cap plunger ) . Known acute chronic , clinically significant system condition , e.g . neurologic , pulmonary , cardiovascular , hepatic , renal functional abnormality psychiatric disorder , determine medical history , physical examination previous laboratory test . History chronic condition ( ) require treatment cancer , chronic hepatic kidney disease ( ) , diabetes , autoimmune disease . This exclusion criterion understood exclusion subject significant medical condition ( cancer , autoimmune disease ) currently treatment . Acute disease time enrolment . Acute disease define presence moderate severe illness without fever . Enrolment deferred condition resolve . All vaccine administer person minor illness diarrhoea , mild upper respiratory infection without lowgrade febrile illness , i.e . oral/ axillary temperature &lt; 37.5 °C ( 99.5 °F ) . A subject body temperature ( i.e . fever ) &gt; 37.5 °C ( 99.5 °F ) . Drug and/or alcohol abuse .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>